Table 2. The baseline characteristics of the selected patients for next-generation sequencing of exosomal microRNAs.
| Fibrosis Gr 0–1 (n = 5) | Fibrosis Gr 2 (n = 5) | Fibrosis Gr 3 (n = 5) | Fibrosis Gr 4 (n = 3) | Total (N = 18) | |
|---|---|---|---|---|---|
| Age | 47 ± 14.75 | 51.8 ± 15.96 | 63.6 ± 7.06 | 67.33 ± 7.02 | 56.33 ± 14.04 |
| Female | 4 (80%) | 5 (100%) | 5 (100%) | 2 (66.7%) | 16 (88.89%) |
| Platelet | 222.5 (180, 233.5) | 186 (181, 196) | 180 (176.5, 268.5) | 159 (138, 179.5) | 191 (173.25, 227.25) |
| Albumin | 4.3 (4.2, 4.4) | 4.5 (4.5, 4.5) | 4.3 (4.3, 4.4) | 4.5 (4.4, 4.55) | 4.4 (4.3, 4.5) |
| Total bilirubin | 0.46 ± 0.21 | 0.48 ± 0.13 | 0.6 ± 0.07 | 0.97 ± 0.72 | 0.59 ± 0.33 |
| AST | 72.6 ± 41.38 | 106 ± 47.93 | 84.4 ± 36.84 | 78 ± 38.57 | 86.06 ± 40.25 |
| ALT | 29 (23, 33) | 77 (35, 117) | 70 (26, 89) | 30 (27.5, 45) | 34 (26.75, 86) |
| PT (INR) | 1.05 ± 0.05 | 1.1 ± 0.06 | 1.1 ± 0.04 | 1.21 ± 0.05 | 1.1 ± 0.07 |
| Child-Pugh score | 5 (5, 5) | 5 (5, 5) | 5 (5, 5) | 5 (5, 5) | 5 (5, 5) |
| MELD score | 7.05 ± 0.46 | 7.46 ± 0.67 | 7.49 ± 0.37 | 9.27 ± 1.6 | 7.66 ± 1.04 |
| Transient elastography (kPa) | 11.86 ± 3.98 | 11.02 ± 2.15 | 16.8 ± 3.08 | 20.3 ± 7.45 | 14.41 ± 5.17 |
AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; INR, international normalized ratio; MELD, model for end stage liver disease
Data are expressed as mean ± standard deviation or median (interquartile range) according to normality test.